The therapeutic landscape of non-alcoholic steatohepatitis

Liver International

Volumn 37, Issue 5, 2017, Pages 634-647

  Perazzo, Hugo ^a   Dufour, Jean François ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

fatty liver; fibrosis; pharmacological treatment; steatohepatitis

Indexed keywords

ACYL COENZYME A DESATURASE 1 INHIBITOR; ALPHA TOCOPHEROL; APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITOR; CASPASE INHIBITOR; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ELAFIBRANOR; FARNESOID X RECEPTOR AGONIST; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GALECTIN 3 PROTEIN INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; OXIDOREDUCTASE INHIBITOR; OXYGENASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; PROTEIN INHIBITOR; PROTEIN LYSINE 6 OXIDASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1 INHIBITOR; VENLAFAXINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; ANTIDIABETIC AGENT; ANTIOXIDANT; CHALCONE DERIVATIVE; CHENODEOXYCHOLIC ACID; PROPIONIC ACID DERIVATIVE;

APOPTOSIS; BARIATRIC SURGERY; BODY WEIGHT LOSS; DIET THERAPY; DISEASE ASSOCIATION; DRUG POTENCY; FATTY ACID OXIDATION; HEALTHY DIET; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METABOLISM; LIVER TUMOR; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; REVIEW; ANALOGS AND DERIVATIVES; COMPLICATION; DISEASE EXACERBATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIOXIDANTS; CHALCONES; CHENODEOXYCHOLIC ACID; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPIONATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; VITAMIN E; WEIGHT LOSS;

EID: 84997765916     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13270     Document Type: Review

References (92)

1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.
2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
3. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238.
4. Perazzo H, Poynard T, Dufour JF. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin Liver Dis. 2014;18:233–248.
5. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.
6. Gitto S, Vukotic R, Vitale G, Pirillo M, Villa E, Andreone P. Non-alcoholic steatohepatitis and liver transplantation. Dig Liver Dis. 2016;48:587–591.
7. Lin SC, Ang B, Hernandez C, et al. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. Therap Adv Gastroenterol. 2016;9:152–161.
8. Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016;9:392–407.
9. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
10. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–845.
11. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392–1405.
12. Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1835–1848.
13. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378.
14. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–388.
15. Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969–1987.
16. Fajas L, Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol. 1998;10:165–173.
17. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968–2974.
18. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–315.
19. Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007;47:565–570.
20. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–39.
21. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–1962.
22. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–1188.
23. Cohen D. FDA puts rosiglitazone post-marketing trial on hold. BMJ. 2010;341:c4017.
24. Yu XH, Zheng XL, Tang CK. Peroxisome proliferator-activated receptor alpha in lipid metabolism and atherosclerosis. Adv Clin Chem. 2015;71:171–203.
25. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720–733.
26. Bojic LA, Huff MW. Peroxisome proliferator-activated receptor delta: a multifaceted metabolic player. Curr Opin Lipidol. 2013;24:171–177.
27. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952.
28. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150:1147–1159.
29. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014;16:63–71.
30. Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013;33:809–816.
31. Wettstein G, Estivalet C, Tessier J, et al. The new generation pan-PPAR agonist IVA337 protects the liver from metabolic disorders and fibrosis. In: 51st Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2016 Barcelona, Spain: J Hepatol. 2016;64:S169–S170.
32. Ruzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis. 2016;75:2175–2183.
33. Taoka H, Yokoyama Y, Morimoto K, et al. Role of bile acids in the regulation of the metabolic pathways. World J Diabetes. 2016;7:260–270.
34. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.
35. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988–997.
36. Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76:1221–1226.
37. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–582.
38. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
39. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
40. Liles JT, Karnik S, Hambruch E, et al. FXR agonism by GS-9674 decreases steatosis and fibrosis in a murine model of NASH. In: 51st Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2016 Barcelona, Spain: J Hepatol. 2016;64:S169.
41. Laffitte B, Young K, Joseph S, et al. A novel, highly potent, non-bile acid FXR agonist for the treatment of NASH and cholestasis. Hep Intl. In: 25th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2016. Tokyo, Japan: 2016;1:S97.
42. Lam IP, Lee LT, Choi HS, Alpini G, Chow BK. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). Am J Physiol Gastrointest Liver Physiol. 2009;297:G90–G97.
43. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159–165.
44. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–253.
45. Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol. 2002;160:2295–2307.
46. Zhou M, Wang X, Phung V, et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014;74:3306–3316.
47. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 2013;78:489–496.
48. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148:774–781.
49. Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016;23:427–440.
50. Ralston JC, Metherel AH, Stark KD, Mutch DM. SCD1 mediates the influence of exogenous saturated and monounsaturated fatty acids in adipocytes: effects on cellular stress, inflammatory markers and fatty acid elongation. J Nutr Biochem. 2016;27:241–248.
51. Leikin-Frenkel A, Gonen A, Shaish A, et al. Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic. Arch Med Res. 2010;41:397–404.
52. Konikoff FM, Gilat T. Effects of fatty acid bile acid conjugates (FABACs) on biliary lithogenesis: potential consequences for non-surgical treatment of gallstones. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:171–175.
53. Zhang Z, Dales NA, Winther MD. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease. J Med Chem. 2014;57:5039–5056.
54. Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085–2091.
55. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
56. Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7:92–107.
57. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690.
58. Trauner M, Halilbasic E, Claudel T, et al. Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis. 2015;33:433–439.
59. Steinacher D, Claudel T, Stojakovic T. NorUDCA reduces liver injury and improves glucose sensitivity in a mouse model of obesity and steatosis. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015 San Francisco, CA United States: Hepatology. 2015;62:689A.
60. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909–916.
61. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004;39:608–616.
62. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211–1221.
63. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377–384.
64. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
65. Koekkoek WA, van Zanten AR. Antioxidant vitamins and trace elements in critical illness. Nutr Clin Pract. 2016;31:457–474.
66. Sokol RJ, McKim JM Jr, Goff MC, et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology. 1998;114:164–174.
67. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842–857.
68. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–1556.
69. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702.
70. Brobey RK, Dheghani M, Foster PP, Kuro OM, Rosenblatt KP. Klotho regulates 14-3-3zeta monomerization and binding to the ASK1 signaling complex in response to oxidative stress. PLoS One. 2015;10:e0141968.
71. Volynets GP, Bdzhola VG, Golub AG, et al. Rational design of apoptosis signal-regulating kinase 1 inhibitors: discovering novel structural scaffold. Eur J Med Chem. 2013;61:104–115.
72. Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125:501–520.
73. Jarolimek W, Charlton B. Phase 1 results from PXS-4728A, a selective SSAO/VAP-1 inhibitor, for the treatment of non-alcoholic steatohepatitis. In: 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2015. Vienna, Austria: J Hepatol. 2015;62:S274–S275.
74. Seki E, de Minicis S, Inokuchi S, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50:185–197.
75. Pradere JP, Kluwe J, De Minicis S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013;58:1461–1473.
76. Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11:e0158156.
77. Thompson M, Saag M, DeJesus E, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2016;30:869–878.
78. Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47:356–365.
79. Cui J, Philo L, Nguyen P, et al. Sitagliptin vs placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65:369–376.
80. McCormack PL. Evogliptin: first global approval. Drugs. 2015;75:2045–2049.
81. Godoy AL, Rocha A, da Silva Souza C, Lanchote VL. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. J Clin Pharmacol. 2016;56:567–575.
82. Ilyas G, Zhao E, Tanaka K, Ravenelle F, Czaja MJ. Oral pentamidine (VLX103) prevents the development of alcoholic liver disease in mice. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015. San Francisco, CA United States: Hepatology. 2015;62:865A.
83. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010;30:402–410.
84. Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
85. Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor—a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010;31:969–978.
86. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16:1095–1105.
87. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610–1619.
88. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10:277–286.
89. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88:660–672.
90. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol. 2005;43:499–507.
91. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–1017.
92. Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013;8:e75361.